Clinical Study on Efficacy and Safety of Escit-alopram VS Citalopram in the Treatment of First-episode Geriatric Depression

Objective:To compare the efficacy and safety of Escit-alopram and Citalopram in the treatment of first-episode geriatric depression.Methods:68 patients with first-episode geriatric depression were randomly divided into group A(Escit-alopram) and group B(Citalopram) for 6 weeks' treatment.Hamilton Depression rating scale(HAMD 17),Clinical Global Impression Scale(CGI) and Treatment Emergent symptom scale(TESS) were used to assess the efficacy and side effects respectively before treatment and after treatment 1、2、4、6 weekends.Results: The scores of HAMD 17 and CGI in the group A were lower than those in the group B in the end of 1、4、6 week,and there was significant difference between the two groups(t=2.18,2.77,3.2,P0.05或P0.01);Clinical efficacy was significant difference between both groups(x2=4.19,P0.05);There was no significant difference in adverse reactions between both groups(x2=0.15,P 0.05).Conclusions: In contrast with Citalopram,Escit-alopram has a better antidepressant effect with faster onset,better efficacy,higher safety and well tolerated,and can not only alleviate the symptoms significantly but also be used as first-line medicine for treating geriatric depression.